当前位置: 首页 >> 检索结果
421. Prostaglandin E1 restores endothelial progenitor cell function in systemic sclerosis.
作者: Judith Potjewijd.;Rachid Tobal.;Steven J Arends.;Lucienne Debrus-Palmans.;Jan G M C Damoiseaux.;Pieter van Paassen.
来源: Rheumatology (Oxford). 2025年64卷8期4761-4765页
SSc is a chronic autoimmune disease characterized by microvascular injury and impaired angiogenesis, with endothelial progenitor cells (EPCs) playing a key role in vascular repair. EPC subsets, including endothelial colony-forming cells (ECFCs) and colony-forming unit-endothelial cells (CFU-ECs), are known to be dysfunctional in SSc, contributing to disease-associated vasculopathy. Prostaglandin E1 (PGE1) is a vasodilator with potential pro-angiogenic effects, but its impact on EPC numbers and function in SSc remains unexplored. This study aimed to investigate whether PGE1 treatment can modulate EPC numbers, specifically CFU-ECs and ECFCs, in patients with SSc and RP, and evaluate its potential role in promoting vascular repair.
422. Intracranial GCA: a comprehensive systematic review.
作者: Sagar Patel.;Iva Okaj.;Jessica Scott.;Sukhreet Atwal.;Colin Stark.;Rabia Tahir.;Nader Khalidi.;Mats Junek.
来源: Rheumatology (Oxford). 2025年64卷8期4517-4524页
GCA is increasingly recognized to occur in intracranial vessels with unknown clinical ramifications. We identified all reported cases of intracranial GCA (ICGCA) in the literature to describe common presentations, investigations, treatments and outcomes.
423. "As long as you learn to adapt"-a longitudinal mixed-methods study exploring the first decade with rheumatoid arthritis.
作者: Maria Bergström.;Åsa Larsson Ranada.;Annette Sverker.;Ingrid Thyberg.;Mathilda Björk.
来源: BMC Rheumatol. 2025年9卷1期35页
Early diagnosis and modern treatment have changed everyday life of patients with rheumatoid arthritis (RA). However, symptoms are still pronounced several years after diagnosis. The aim of this study is therefore to synthesise the perception of everyday life in men and women with contemporary treated RA over the course of the first decade after diagnosis. This will be achieved by comparing subjective experiences with quantitative measures of disability and disease activity.
424. Gout incidence in metformin versus sodium-glucose co-transporter-2 inhibitor users: a retrospective cohort study.
作者: Masaki Hatano.;Akira Okada.;Yusuke Sasabuchi.;Hisatoshi Ishikura.;Takeyuki Tanaka.;Taku Saito.;Sakae Tanaka.;Hideo Yasunaga.
来源: Rheumatology (Oxford). 2025年64卷7期4164-4171页
To compare the incidence of gout in individuals with diabetes receiving metformin vs sodium-glucose co-transporter-2 inhibitors (SGLT-2is).
426. The status and correlation factors of fatigue in patients with ankylosing spondylitis (FACIT-F): a cross-sectional study based on the Chinese population.
作者: Tiantian Sun.;Kun Yang.;Yuening Chen.;Zhaoyang Geng.;Xinning Qu.;Qing Yu.;Hongxiao Liu.
来源: BMC Rheumatol. 2025年9卷1期34页
To analyze the status and correlation factors of fatigue in patients with ankylosing spondylitis (AS), and provide a reference for improving the fatigue status of patients with AS.
427. How have the clinical, laboratory, treatment features and outcomes in children with lupus nephritis progressed over the last 30 years?
作者: Deniz Gezgin Yıldırım.;Nihal Karaçayır.;Hakan Kısaoğlu.;Aydan Yekedüz Bülbül.;Pınar Garipçin.;Hülya Nalçacıoğlu.;Mukaddes Kalyoncu.;Hakan Poyrazoğlu.;Sevcan A Bakkaloğlu.
来源: Rheumatology (Oxford). 2025年64卷7期4275-4282页
Management of systemic lupus erythematosus (SLE) through new treatment options has improved lupus nephritis (LN) prognosis. The aim of this study was to compare the changes in the demographic, laboratory, and treatment characteristics, prognosis, and outcomes of paediatric-onset LN patients over 30 years.
428. Executive Summary: The British Society for Rheumatology guideline for the management of foot health in inflammatory arthritis.
作者: Lara S Chapman.;Michael Backhouse.;Nadia Corp.;Danielle van der Windt.;Lindsay Bearne.;Lindsey Cherry.;Gavin Cleary.;Jasmine Davey.;Rachel Ferguson.;Philip Helliwell.;Adam Lomax.;Helen McKeeman.;Alan A Rawlings.;Robin Rees.;Robbie Rooney.;Sarah Ryan.;Lucy Sanders.;Heidi J Siddle.;Sue Varley.;Louise Warburton.;Jim Woodburn.;Edward Roddy.; .
来源: Rheumatology (Oxford). 2025年64卷5期2347-2354页 429. The British Society for Rheumatology guideline for the management of foot health in inflammatory arthritis.
作者: Lara S Chapman.;Michael Backhouse.;Nadia Corp.;Danielle van der Windt.;Lindsay Bearne.;Lindsey Cherry.;Gavin Cleary.;Jasmine Davey.;Rachel Ferguson.;Philip Helliwell.;Adam Lomax.;Helen McKeeman.;Alan A Rawlings.;Robin Rees.;Robbie Rooney.;Sarah Ryan.;Lucy Sanders.;Heidi J Siddle.;Sue Varley.;Louise Warburton.;Jim Woodburn.;Edward Roddy.; .
来源: Rheumatology (Oxford). 2025年64卷5期2355-2368页 430. Genetically-determined variation in CRP impacts disease activity assessment in rheumatoid arthritis.
作者: Thomas R Riley.;Austin M Wheeler.;Grant W Cannon.;Brian Sauer.;Katherine D Wysham.;Bryant R England.;Kristin Wipfler.;Kaleb Michaud.;Michael March.;Scott M Damrauer.;Anurag Verma.;Michael D George.;Ted R Mikuls.;Joshua F Baker.
来源: Rheumatology (Oxford). 2025年64卷6期3921-3928页
In patients with RA, we evaluated a single-nucleotide variant previously associated with lower CRP to assess if this impacts clinical disease activity assessments including the disease activity score-28 with CRP (DAS28(CRP)).
432. The impact of changes in fibromyalgia diagnosis criteria: using NAMCS data (2010-2019) to identify trends.
Fibromyalgia is currently diagnosed under the 2016 research criteria, a combination of the 2010 and 2011 criteria revisions. The current guidelines have led to ongoing misdiagnosis issues dating back to the criteria initially established by the 1990 American College of Rheumatology (ACR). Given the extensive revisions to the diagnostic criteria in 2016, instances of over-and under-diagnosing as well as measurement errors corresponding to the different diagnostic criteria utilized, the current study sought to investigate changes in the incidence of fibromyalgia diagnoses and the associations between fibromyalgia diagnosis and relevant comorbidities and somatic symptoms of interest.
433. Do MRI-detected erosions in the RA-risk phase of arthralgia reflect current or imminent radiographic erosions? A large longitudinal imaging study.
作者: Quirine A Dumoulin.;Annette H M van der Helm-van Mil.;Hanna W van Steenbergen.
来源: Rheumatology (Oxford). 2025年64卷7期4200-4206页
Radiographic erosions of hands and feet are a hallmark of rheumatoid arthritis (RA) and treatment aims to prevent radiographic progression. In the at-risk phase of clinically suspect arthralgia (CSA), erosions on radiographs are rare but can be visible on MRI, which is a more sensitive imaging technique. However, the value of these MRI erosions and especially the relation with radiographic erosions is unknown. Therefore, we aimed to study if MRI-detected erosions in CSA (i) correspond with simultaneous radiographic erosions and (ii) associate with local radiographic progression.
434. Belumosudil in diffuse cutaneous systemic sclerosis: a randomized, double-blind, open-label extension, placebo-controlled, phase 2 study.
作者: Lorinda Chung.;Richard M Silver.;Virginia Steen.;Daniel E Furst.;Flavia V Castelino.;Marcin Trojanowski.;Robert Spiera.;Robyn Domsic.;Alicia Rodriguez-Pla.;Tamiko R Katsumoto.;Helene Goulaouic.;Hong Wang.;Melanie Espinasse.;Souheil El-Chemaly.;Rui Wang.
来源: Rheumatology (Oxford). 2025年64卷7期4299-4308页
To determine the efficacy, safety and pharmacodynamics of belumosudil in patients with diffuse cutaneous systemic sclerosis (dcSSc) treated with background immunosuppressive therapies.
435. Terminologies and definitions used to classify patients with osteoarthritis: a scoping review.
作者: Gabriel Gijon-Nogueron.;Peter Balint.;Anastas Batalov.;Predrag Ostojic.;Nico Sollmann.;Marienke van Middelkoop.;Rintje Agricola.;Josefine E Naili.;Darko Milovanovic.;Stanislava Popova.;Maria Kazakova.;Sylvia Nuernberger.;Cecilia Aulin.;Rositsa Karalilova.;Yves Henrotin.
来源: BMC Rheumatol. 2025年9卷1期32页
Osteoarthritis (OA), a prevalent and disabling condition, significantly burdens individuals and healthcare systems worldwide. It is characterized by joint pain, stiffness, and structural changes in cartilage, bone, and synovium. The clinical manifestations of OA vary widely, reflecting complex interactions among genetic, metabolic, biomechanical, and environmental factors. Despite progress in identifying OA clinical phenotypes, inconsistent terminology, including "phenotypes," "subtypes," and "subgroups," hinders effective communication and research translation. This review aims to synthesize existing literature on clinical OA phenotypes, terminology, and definitions and propose a research agenda.
436. Complex crosstalk: early-onset lupus and antiphospholipid syndrome in a child with SHOC2-related RASopathy.
作者: Bengisu Menentoğlu.;Esma Nur Konur Akbaş.;Gülşah Kavrul Kayaalp.;Özlem Akgün.;Ayça Dilruba Aslanger.;Zehra Oya Uyguner.;Nuray Aktay Ayaz.
来源: Rheumatology (Oxford). 2025年64卷8期4852-4853页 437. Belimumab efficacy in mucocutaneous manifestations of systemic lupus erythematosus: a large post hoc analysis of five phase III clinical trials.
作者: Giorgia Grosso.;Nefeli Giannopoulou.;Alexander Tsoi.;Nursen Cetrez.;Dionysis Nikolopoulos.;Julius Lindblom.;Ioannis Parodis.
来源: Rheumatology (Oxford). 2025年64卷7期4257-4266页
To determine the efficacy of belimumab on mucocutaneous manifestations of SLE in a large integrative analysis.
438. A systematic review and meta-analysis of the response to placebo in clinical trials of inclusion body myositis.
作者: Elie Naddaf.;Michael P Skolka.;Larry Prokop.;Mazen M Dimachkie.;Jean-Yves Hogrel.;Olivier Benveniste.;Zhen Wang.;Jay Mandrekar.;Colin P West.;M Hassan Murad.
来源: Rheumatology (Oxford). 2025年64卷7期4125-4132页
IBM is characterized by slowly progressive muscle weakness making it challenging to detect significant changes in weakness during a clinical trial. Trial participants receiving placebo may behave differently from in natural history studies. We aimed to quantify the change in muscle strength and IBM Functional Rating Scale (IBMFRS) of IBM patients receiving placebo during clinical trials.
439. Distinct landscapes of fibroblast subtypes in arteries of patients with giant cell arteritis.
作者: Shuang Xu.;William F Jiemy.;Yannick van Sleen.;Johanna Westra.;Jacoba C Graver.;Kornelis S M van der Geest.;Peter Heeringa.;Annemieke M H Boots.;Elisabeth Brouwer.;Maria Sandovici.
来源: Rheumatology (Oxford). 2025年64卷7期4382-4392页
Giant cell arteritis (GCA) is a systemic vasculitis of large- and medium-sized arteries characterized by granulomatous inflammation and vascular remodelling. Although fibroblasts are the predominant cell type in the adventitia, their role in GCA pathogenesis is largely unknown. This study aimed to investigate the distribution of fibroblast subtypes in relation to vascular remodelling in GCA.
440. Treatments for enhancing sleep quality in fibromyalgia: a systematic review and meta-analysis.
作者: Anna Pathak.;Eoin M Kelleher.;Isabelle Brennan.;Raj Amarnani.;Amanda Wall.;Robert Murphy.;Hopin Lee.;Beth Fordham.;Anushka Irani.
来源: Rheumatology (Oxford). 2025年64卷8期4495-4516页
Sleep disturbance is a key symptom of fibromyalgia and a risk factor for chronic widespread pain. This systematic review and meta-analysis aims to assess the effectiveness of pharmacological treatments and cognitive behavioural therapy (CBT) in improving sleep quality in fibromyalgia patients.
|